Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights

Baha Sharaf,1 Faris Tamimi,1 Haneen Al-Abdallat,2 Suhaib Khater,1 Osama Salama,1 Anas Zayed,1 Osama El Khatib,1 Assem Qaddoumi,1 Malek Horani,1 Yosra AL-Masri,1 Wafa Asha,1 Bayan Altalla’,1 Hira Bani Hani,1 Hikmat Abdel-Razeq1,2 1King Hussein Cancer Center, Amman, Jordan; 2School of Medicine, The Un...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, El Khatib O, Qaddoumi A, Horani M, AL-Masri Y, Asha W, Altalla’ B, Bani Hani H, Abdel-Razeq H
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Dove Medical Press 2025-03-01
Serie:	Biologics: Targets & Therapy
Soggetti:	dual anti-her2 regimen pertuzumab trastuzumab breast cancer neoadjuvant
Accesso online:	https://www.dovepress.com/dual-anti-her2-therapy-vs-trastuzumab-alone-with-neoadjuvant-anthracyc-peer-reviewed-fulltext-article-BTT
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!